429 related articles for article (PubMed ID: 17222678)
21. Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland.
Nelson CP; Gupta P; Napier CM; Nahorski SR; Challiss RA
J Pharmacol Exp Ther; 2004 Sep; 310(3):1255-65. PubMed ID: 15140916
[TBL] [Abstract][Full Text] [Related]
22. In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.
Maruyama S; Hasuike N; Suzuki K; Yamada S
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):463-71. PubMed ID: 18074121
[TBL] [Abstract][Full Text] [Related]
23. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
Kobayashi F; Yageta Y; Segawa M; Matsuzawa S
Arzneimittelforschung; 2007; 57(2):92-100. PubMed ID: 17396619
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodents.
Nagabukuro H; Villa KL; Wickham LA; Kulick AA; Gichuru L; Donnelly MJ; Voronin GO; Pereira T; Tong X; Nichols A; Alves SE; O'Neill GP; Johnson CV; Hickey EJ
J Pharmacol Exp Ther; 2011 Jul; 338(1):220-7. PubMed ID: 21459965
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Ohtake A; Saitoh C; Yuyama H; Ukai M; Okutsu H; Noguchi Y; Hatanaka T; Suzuki M; Sato S; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):54-8. PubMed ID: 17202659
[TBL] [Abstract][Full Text] [Related]
26. Muscarinic receptors in the bladder: from basic research to therapeutics.
Hegde SS
Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S80-7. PubMed ID: 16465186
[TBL] [Abstract][Full Text] [Related]
27. Tolterodine does not affect memory assessed by passive-avoidance response test in mice.
Cappon GD; Bush B; Newgreen D; Finch GL; Alper RH
Eur J Pharmacol; 2008 Jan; 579(1-3):225-8. PubMed ID: 18031724
[TBL] [Abstract][Full Text] [Related]
28. Tolterodine.
Hills CJ; Winter SA; Balfour JA
Drugs; 1998 Jun; 55(6):813-20; discussion 821-2. PubMed ID: 9617596
[TBL] [Abstract][Full Text] [Related]
29. Fesoterodine, its active metabolite, and tolterodine bind selectively to muscarinic receptors in human bladder mucosa and detrusor muscle.
Yoshida A; Fuchihata Y; Kuraoka S; Osano A; Otsuka A; Ozono S; Takeda M; Masuyama K; Araki I; Yamada S
Urology; 2013 Apr; 81(4):920.e1-5. PubMed ID: 23497983
[TBL] [Abstract][Full Text] [Related]
30. Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder.
Yamada S; Seki M; Ogoda M; Fukata A; Nakamura M; Ito Y
J Pharmacol Exp Ther; 2011 Feb; 336(2):365-71. PubMed ID: 21047953
[TBL] [Abstract][Full Text] [Related]
31. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
[TBL] [Abstract][Full Text] [Related]
32. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
Perfetto EM; Subedi P; Jumadilova Z
Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388
[TBL] [Abstract][Full Text] [Related]
33. Tolterodine for treatment of overactive bladder.
Kanofsky JA; Nitti VW
Urol Clin North Am; 2006 Nov; 33(4):447-53, viii. PubMed ID: 17011380
[TBL] [Abstract][Full Text] [Related]
34. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
[TBL] [Abstract][Full Text] [Related]
35. Tolterodine use for symptoms of overactive bladder.
Ruscin JM; Morgenstern NE
Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
[TBL] [Abstract][Full Text] [Related]
36. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years.
Olshansky B; Ebinger U; Brum J; Egermark M; Viegas A; Rekeda L
J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):241-51. PubMed ID: 18832343
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.
Kay G; Crook T; Rekeda L; Lima R; Ebinger U; Arguinzoniz M; Steel M
Eur Urol; 2006 Aug; 50(2):317-26. PubMed ID: 16687205
[TBL] [Abstract][Full Text] [Related]
38. Tissue distribution of tolterodine, a muscarinic receptor antagonist, and transfer into fetus and milk in mice.
Påhlman I; d'Argy R; Nilvebrant L
Arzneimittelforschung; 2001 Feb; 51(2):125-33. PubMed ID: 11258042
[TBL] [Abstract][Full Text] [Related]
39. Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.
Colli E; Parazzini F; Olivieri L; Cipriani S; Bertozzi R; Meschia M; Montorsi F
Eur Urol; 2007 Aug; 52(2):525-30. PubMed ID: 17449169
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics.
Påhlman I; Kankaanranta S; Palmér L
Arzneimittelforschung; 2001 Feb; 51(2):134-44. PubMed ID: 11258043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
